Abstract
G protein-coupled receptor 55 (GPR55) shares numerous cannabinoid ligands with CB1 and CB2 receptors despite low homology with those classical cannabinoid receptors. The pharmacology of GPR55 is not yet fully elucidated; however, GPR55 utilizes a different signaling system and downstream cascade associated with the receptor. Therefore, GPR55 has emerged as a putative "type 3" cannabinoid receptor, establishing a novel class of cannabinoid receptor. Furthermore, the recent evidence of GPR55-CB1 and GPR55-CB2 heteromerization along with its broad distribution from central nervous system to peripheries suggests the importance of GPR55 in various cellular processes and pathologies and as a potential therapeutic target in inflammation.
Original language | English |
---|---|
Pages (from-to) | 297-302 |
Number of pages | 6 |
Journal | Journal of Basic and Clinical Physiology and Pharmacology |
Volume | 27 |
Issue number | 3 |
DOIs | |
Publication status | Published - May 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 by De Gruyter.
ASJC Scopus Subject Areas
- Physiology
- Pharmacology
- Drug Discovery
PubMed: MeSH publication types
- Journal Article
- Review